NO315689B1 - Farmasöytisk tablett omfattende famciclovir og fremgangsmåte for å fremstille denne - Google Patents
Farmasöytisk tablett omfattende famciclovir og fremgangsmåte for å fremstille denne Download PDFInfo
- Publication number
- NO315689B1 NO315689B1 NO19983259A NO983259A NO315689B1 NO 315689 B1 NO315689 B1 NO 315689B1 NO 19983259 A NO19983259 A NO 19983259A NO 983259 A NO983259 A NO 983259A NO 315689 B1 NO315689 B1 NO 315689B1
- Authority
- NO
- Norway
- Prior art keywords
- famciclovir
- tablet
- pharmaceutical tablet
- pharmaceutical
- tablets
- Prior art date
Links
- 229960004396 famciclovir Drugs 0.000 title claims description 23
- GGXKWVWZWMLJEH-UHFFFAOYSA-N famcyclovir Chemical compound N1=C(N)N=C2N(CCC(COC(=O)C)COC(C)=O)C=NC2=C1 GGXKWVWZWMLJEH-UHFFFAOYSA-N 0.000 title claims description 23
- 238000000034 method Methods 0.000 title claims description 5
- 238000002360 preparation method Methods 0.000 title description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 12
- 239000004480 active ingredient Substances 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 4
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 4
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 4
- 239000008101 lactose Substances 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 3
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 238000007906 compression Methods 0.000 description 5
- 230000006835 compression Effects 0.000 description 5
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- JNTOCHDNEULJHD-UHFFFAOYSA-N Penciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(CCC(CO)CO)C=N2 JNTOCHDNEULJHD-UHFFFAOYSA-N 0.000 description 2
- 229960004977 anhydrous lactose Drugs 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 229960001179 penciclovir Drugs 0.000 description 2
- 229940079832 sodium starch glycolate Drugs 0.000 description 2
- 229920003109 sodium starch glycolate Polymers 0.000 description 2
- 239000008109 sodium starch glycolate Substances 0.000 description 2
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 208000009889 Herpes Simplex Diseases 0.000 description 1
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 1
- 241000701074 Human alphaherpesvirus 2 Species 0.000 description 1
- 241000701085 Human alphaherpesvirus 3 Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 238000007580 dry-mixing Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 229960001375 lactose Drugs 0.000 description 1
- 229940057948 magnesium stearate Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229940080313 sodium starch Drugs 0.000 description 1
- 239000012453 solvate Chemical class 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9600847.9A GB9600847D0 (en) | 1996-01-16 | 1996-01-16 | Pharmaceuticals |
| PCT/EP1997/000195 WO1997025990A1 (en) | 1996-01-16 | 1997-01-13 | High-content famciclovir tablets |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO983259D0 NO983259D0 (no) | 1998-07-15 |
| NO983259L NO983259L (no) | 1998-07-15 |
| NO315689B1 true NO315689B1 (no) | 2003-10-13 |
Family
ID=10787105
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO19983259A NO315689B1 (no) | 1996-01-16 | 1998-07-15 | Farmasöytisk tablett omfattende famciclovir og fremgangsmåte for å fremstille denne |
Country Status (38)
| Country | Link |
|---|---|
| US (1) | US6765007B1 (ja) |
| EP (1) | EP0874632B1 (ja) |
| JP (2) | JP4711360B2 (ja) |
| KR (1) | KR100338829B1 (ja) |
| CN (1) | CN1132582C (ja) |
| AP (2) | AP747A (ja) |
| AR (1) | AR005456A1 (ja) |
| AT (1) | ATE220910T1 (ja) |
| AU (1) | AU713090B2 (ja) |
| BG (1) | BG63488B1 (ja) |
| BR (1) | BR9706982A (ja) |
| CY (1) | CY2390B1 (ja) |
| CZ (1) | CZ287205B6 (ja) |
| DE (1) | DE69714215T2 (ja) |
| DK (1) | DK0874632T3 (ja) |
| DZ (1) | DZ2159A1 (ja) |
| EA (1) | EA001946B1 (ja) |
| EG (1) | EG23684A (ja) |
| ES (1) | ES2180922T3 (ja) |
| GB (1) | GB9600847D0 (ja) |
| HK (1) | HK1016473A1 (ja) |
| HU (1) | HU225472B1 (ja) |
| IL (1) | IL124913A0 (ja) |
| MX (1) | MX9805713A (ja) |
| MY (1) | MY127527A (ja) |
| NO (1) | NO315689B1 (ja) |
| NZ (1) | NZ326769A (ja) |
| OA (1) | OA10812A (ja) |
| PE (1) | PE35498A1 (ja) |
| PL (1) | PL187291B1 (ja) |
| PT (1) | PT874632E (ja) |
| SK (1) | SK282132B6 (ja) |
| TR (1) | TR199800954T2 (ja) |
| TW (1) | TW434016B (ja) |
| UA (1) | UA63897C2 (ja) |
| UY (2) | UY24437A1 (ja) |
| WO (1) | WO1997025990A1 (ja) |
| ZA (1) | ZA97310B (ja) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100136106A1 (en) * | 2005-06-08 | 2010-06-03 | Gary Liversidge | Modified Release Famciclovir Compositions |
| ES2401008T3 (es) | 2009-06-26 | 2013-04-16 | Taris Biomedical, Inc. | Comprimidos farmacéuticos sólidos para dispositivos implantables para la administración de fármacos |
| JP2015063521A (ja) * | 2013-09-02 | 2015-04-09 | 科研製薬株式会社 | 高い薬物含有率を有する錠剤及びその製造方法 |
| CN104434852B (zh) * | 2013-09-18 | 2018-11-20 | 北京韩美药品有限公司 | 泛昔洛韦直压片及其制备方法 |
| CN112587491B (zh) * | 2021-01-03 | 2022-08-23 | 迪沙药业集团有限公司 | 一种泛昔洛韦片组合物 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3421800C1 (de) * | 1984-06-12 | 1986-04-17 | Maschinen und Werkzeugbau Michael Brümmer GmbH, 8804 Dinkelsbühl | Elastische Walze zum Behandeln einer thermoplastischen Folie |
| DE3582399D1 (de) * | 1984-09-20 | 1991-05-08 | Beecham Group Plc | Purin-derivate und ihre pharmazeutische verwendung. |
| SK282071B6 (sk) * | 1991-01-30 | 2001-10-08 | The Wellcome Foundation Limited | Tableta dispergovateľná vo vode a spôsob jej prípravy |
| CA2103050A1 (en) | 1991-05-15 | 1992-11-16 | Yung-Chi Cheng | Determination of prodrugs metabolizable by the liver and therapeutic use thereof |
| GB9303157D0 (en) * | 1993-02-17 | 1993-03-31 | Scotia Holdings Plc | Treatment of a group of related disorders |
| IL111138A (en) | 1993-10-05 | 1997-04-15 | Smithkline Beecham Plc | Pharmaceutical compositions comprising penciclovir and/or its bioprecursor and/or its derivatives for the treatment and prophylaxis of post-herpetic neuralgia |
| JP3702594B2 (ja) * | 1997-08-07 | 2005-10-05 | 株式会社明電舎 | パラメータ調節方法及び装置 |
-
1996
- 1996-01-16 GB GBGB9600847.9A patent/GB9600847D0/en active Pending
-
1997
- 1997-01-02 AP APAP/P/1997/000911A patent/AP747A/en active
- 1997-01-10 UY UY24437A patent/UY24437A1/es not_active IP Right Cessation
- 1997-01-13 NZ NZ326769A patent/NZ326769A/xx not_active IP Right Cessation
- 1997-01-13 AU AU15418/97A patent/AU713090B2/en not_active Expired
- 1997-01-13 IL IL12491397A patent/IL124913A0/xx not_active IP Right Cessation
- 1997-01-13 AP APAP/P/1998/001298A patent/AP1114A/en active
- 1997-01-13 KR KR1019980705371A patent/KR100338829B1/ko not_active IP Right Cessation
- 1997-01-13 DK DK97901539T patent/DK0874632T3/da active
- 1997-01-13 EP EP97901539A patent/EP0874632B1/en not_active Expired - Lifetime
- 1997-01-13 UA UA98063199A patent/UA63897C2/uk unknown
- 1997-01-13 BR BR9706982A patent/BR9706982A/pt not_active IP Right Cessation
- 1997-01-13 TR TR1998/00954T patent/TR199800954T2/xx unknown
- 1997-01-13 DE DE69714215T patent/DE69714215T2/de not_active Expired - Lifetime
- 1997-01-13 AT AT97901539T patent/ATE220910T1/de active
- 1997-01-13 WO PCT/EP1997/000195 patent/WO1997025990A1/en active IP Right Grant
- 1997-01-13 PL PL97327922A patent/PL187291B1/pl unknown
- 1997-01-13 JP JP52569297A patent/JP4711360B2/ja not_active Expired - Lifetime
- 1997-01-13 US US09/101,926 patent/US6765007B1/en not_active Expired - Lifetime
- 1997-01-13 EA EA199800573A patent/EA001946B1/ru not_active IP Right Cessation
- 1997-01-13 CZ CZ19982254A patent/CZ287205B6/cs not_active IP Right Cessation
- 1997-01-13 CN CN97191703A patent/CN1132582C/zh not_active Expired - Lifetime
- 1997-01-13 HU HU9901021A patent/HU225472B1/hu unknown
- 1997-01-13 SK SK956-98A patent/SK282132B6/sk not_active IP Right Cessation
- 1997-01-13 ES ES97901539T patent/ES2180922T3/es not_active Expired - Lifetime
- 1997-01-13 PT PT97901539T patent/PT874632E/pt unknown
- 1997-01-14 TW TW086100335A patent/TW434016B/zh not_active IP Right Cessation
- 1997-01-14 EG EG4697A patent/EG23684A/xx active
- 1997-01-14 AR ARP970100130A patent/AR005456A1/es active IP Right Grant
- 1997-01-15 MY MYPI97000137A patent/MY127527A/en unknown
- 1997-01-15 PE PE1997000022A patent/PE35498A1/es not_active IP Right Cessation
- 1997-01-15 ZA ZA9700310A patent/ZA97310B/xx unknown
- 1997-01-15 DZ DZ970004A patent/DZ2159A1/fr active
- 1997-05-16 UY UY24556A patent/UY24556A1/es not_active IP Right Cessation
-
1998
- 1998-07-15 MX MX9805713A patent/MX9805713A/es unknown
- 1998-07-15 BG BG102638A patent/BG63488B1/bg unknown
- 1998-07-15 NO NO19983259A patent/NO315689B1/no not_active IP Right Cessation
- 1998-07-16 OA OA9800116A patent/OA10812A/en unknown
-
1999
- 1999-04-08 HK HK99101423A patent/HK1016473A1/xx not_active IP Right Cessation
-
2003
- 2003-11-28 CY CY0300085A patent/CY2390B1/xx unknown
-
2008
- 2008-11-19 JP JP2008295818A patent/JP2009091362A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2313783C (en) | Pharmaceutical compositions of (e)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl]-(3r,5s)-3,5-dihydroxyhept-6-enoic acid or a salt thereof | |
| JP3037757B2 (ja) | パロキセチン錠およびその製法 | |
| NO317181B1 (no) | Faste orale doseringsformer av valsartan | |
| CA2000763C (en) | Dispersable formulation | |
| WO2005013964A1 (ja) | ナテグリニド含有製剤 | |
| EP1334732B1 (en) | Pharmaceutical preparation of n-[2-(1,6,7,8-tetrahydro-2h-indeno[5,4 b]furan-8-yl)ethyl]propionamide coated with a copolyvidone-containing coating free of polyethylene glycol | |
| JP2009091362A6 (ja) | 高含量ファムシクロビル錠剤 | |
| JP2009091362A (ja) | 高含量ファムシクロビル錠剤 | |
| PL186915B1 (pl) | Tabletka zawierająca kwas tolfenamowy lub jego farmaceutycznie dopuszczalną sól i sposób wytwarzania takiej tabletki | |
| JPH1121236A (ja) | ロキソプロフェン・ナトリウム固形製剤 | |
| CA2240462C (en) | High-content famciclovir tablets | |
| JP2000229855A (ja) | プラバスタチンナトリウム錠 | |
| HU191542B (en) | Process for production of pastiles containing dipyridamel independent from ph with regulated output of the active substance | |
| JP2009538905A (ja) | 感湿性薬物を含んで成る安定性製剤及びその製造方法 | |
| CN104095850B (zh) | 一种稳定的匹伐他汀钙药物组合物及其制备方法 | |
| HUT67577A (en) | Process for production of adsorbate comprising adjuvant-mixture and non-solid active agent using production of preparations | |
| CA2343949A1 (en) | Benazepril hydrochloride tablet formulations | |
| US7105178B2 (en) | Cardiotonic composition | |
| NZ530973A (en) | Pharmaceutical formulation containing an LTB4 antagonist | |
| JP2001064159A (ja) | 複合顆粒剤 | |
| JPH11302200A (ja) | 崩壊性の改善されたｌ−グルタミン及びメタケイ酸アルミン酸マグネシウム含有製剤 | |
| WO2008008057A1 (en) | Stable formulation comprising a combination of a moisture sensitive drug and a second drug and manufacturing procedure thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK1K | Patent expired |